• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Hercules Capital Announces the Appointment of Ms. Pam Randhawa to Its Board of Directors

    10/20/21 6:00:00 AM ET
    $HCXY
    $HTGC
    $MCK
    Investment Managers
    Finance
    Other Pharmaceuticals
    Health Care
    Get the next $HCXY alert in real time by email

    Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that Pam Randhawa was appointed to serve as a member of its board of directors, effective November 1, 2021. Ms. Randhawa is a thought leader within the life sciences sector and an experienced industry executive, with more than 20 years of experience leading public and private companies, ranging from biotech, healthcare and sustainable solutions, through their various stages of growth.

    Ms. Randhawa will serve on the Nominating and Corporate Governance Committee.

    "Pam's deep industry experience and executive leadership credentials in healthcare and life sciences companies at various stages and sizes will be a valuable addition to our Board of Directors," said Scott Bluestein, chief executive officer and chief investment officer of Hercules. "Pam has made significant contributions to the broader life sciences community through her Board of Director roles at the Massachusetts Biotechnology Council and Massachusetts Life Sciences Center."

    Bluestein added, "Over the past several years, we have enhanced the quality of our directors by assembling highly experienced executives, owners, and operators in the sectors where we provide flexible growth capital and a diversified team to serve on our Board. We're excited by the collective expertise each member of our Board brings as we continue to position the Company for long-term growth and strong shareholder returns. We are pleased to welcome Pam to our Board and look forward to her contributions."

    Ms. Randhawa has over 20 years of business leadership experience in the healthcare and life sciences industries and brings to Hercules a wide range of expertise ranging from policy, corporate strategy, product development, advanced analytics and marketing for Fortune 500 companies, startups and government entities. Since 2013, she has served as Chief Executive Officer and Founder at Empiriko Corporation, a company that has developed a novel in vitro biomimetic platform to accelerate small molecule drug development and is developing a point-of-care diagnostic platform for personalized immunologic/genetic biomarker and drug monitoring. Prior to founding Empiriko, Ms. Randhawa was President and Co-Founder of AgroGreen Biofuels, an alternative biofuels technology company. She has held several executive positions with major healthcare technology companies, including McKesson Corporation (NYSE:MCK), Phase Forward (acquired by Oracle), InfoMedics and Sermo.

    Ms. Randhawa currently serves on the Board of Directors of the Massachusetts Life Sciences Center and as Vice Chair of the Board of Directors of the Massachusetts Biotech Technology Council (MassBio).

    Ms. Randhawa received her Bachelor of Science degree in Economics from the University of Rajasthan and her Master in Public Management degree from Carnegie Mellon University.

    About Hercules Capital, Inc.

    Hercules Capital, Inc. (NYSE:HTGC) is the leading and largest specialty finance company focused on providing senior secured venture growth loans to high-growth, innovative venture capital-backed companies in a broad variety of technology, life sciences and sustainable and renewable technology industries. Since inception (December 2003), Hercules has committed more than $12.0 billion to over 530 companies and is the lender of choice for entrepreneurs and venture capital firms seeking growth capital financing. Companies interested in learning more about financing opportunities should contact [email protected], or call 650.289.3060.

    Hercules Capital, through its wholly owned subsidiary, Hercules Adviser LLC ("Hercules Adviser"), also maintains an asset management business through which it manages investments for external parties. Hercules Adviser is registered as an investment adviser under the Investment Advisers Act of 1940.

    Hercules' common stock trades on the New York Stock Exchange (NYSE) under the ticker symbol "HTGC." In addition, Hercules has one retail bond issuance of 6.25% Notes due 2033 (NYSE:HCXY).

    Forward-Looking Statements

    This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. You should understand that under Section 27A(b)(2)(B) of the Securities Act of 1933, as amended, and Section 21E(b)(2)(B) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 do not apply to forward-looking statements made in periodic reports we file under the Exchange Act.

    The information disclosed in this press release is made as of the date hereof and reflects Hercules' most current assessment of its historical financial performance. Actual financial results filed with the SEC may differ from those contained herein due to timing delays between the date of this release and confirmation of final audit results. These forward-looking statements are not guarantees of future performance and are subject to uncertainties and other factors that could cause actual results to differ materially from those expressed in the forward-looking statements including, without limitation, the risks, uncertainties, including the uncertainties surrounding the current market volatility, and other factors the Company identifies from time to time in its filings with the SEC. Although Hercules believes that the assumptions on which these forward-looking statements are based are reasonable, any of those assumptions could prove to be inaccurate and, as a result, the forward-looking statements based on those assumptions also could be incorrect. You should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this release are made as of the date hereof, and Hercules assumes no obligation to update the forward-looking statements for subsequent events.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20211020005259/en/

    Get the next $HCXY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HCXY
    $HTGC
    $MCK

    CompanyDatePrice TargetRatingAnalyst
    Hercules Capital Inc.
    $HTGC
    12/12/2024$19.50 → $21.50Mkt Perform → Outperform
    Keefe Bruyette
    McKesson Corporation
    $MCK
    12/4/2024$630.00Neutral
    Mizuho
    McKesson Corporation
    $MCK
    11/7/2024$531.00 → $688.00Neutral → Outperform
    Robert W. Baird
    McKesson Corporation
    $MCK
    9/24/2024$603.00 → $531.00Outperform → Neutral
    Robert W. Baird
    McKesson Corporation
    $MCK
    9/5/2024$670.00 → $665.00Outperform
    Leerink Partners
    McKesson Corporation
    $MCK
    8/8/2024$540.00 → $570.00Neutral
    Mizuho
    McKesson Corporation
    $MCK
    2/26/2024$600.00Outperform
    Leerink Partners
    Hercules Capital Inc.
    $HTGC
    1/16/2024$17.00 → $17.50Buy → Neutral
    Compass Point
    More analyst ratings

    $HCXY
    $HTGC
    $MCK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Meyer Seth H covered exercise/tax liability with 4,577 shares, decreasing direct ownership by 1% to 384,630 units (SEC Form 4)

      4 - Hercules Capital, Inc. (0001280784) (Issuer)

      4/15/25 7:33:58 PM ET
      $HTGC
      Investment Managers
      Finance
    • Chief Operating Officer Follmann Christian covered exercise/tax liability with 829 shares, decreasing direct ownership by 0.68% to 120,951 units (SEC Form 4)

      4 - Hercules Capital, Inc. (0001280784) (Issuer)

      4/15/25 7:33:37 PM ET
      $HTGC
      Investment Managers
      Finance
    • Chief Legal Officer & CCO Botelho Kiersten Zaza covered exercise/tax liability with 788 shares, decreasing direct ownership by 1% to 67,563 units (SEC Form 4)

      4 - Hercules Capital, Inc. (0001280784) (Issuer)

      4/15/25 7:33:16 PM ET
      $HTGC
      Investment Managers
      Finance

    $HCXY
    $HTGC
    $MCK
    SEC Filings

    See more
    • McKesson Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - MCKESSON CORP (0000927653) (Filer)

      5/8/25 4:06:16 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • Hercules Capital Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

      8-K - Hercules Capital, Inc. (0001280784) (Filer)

      5/1/25 4:30:18 PM ET
      $HTGC
      Investment Managers
      Finance
    • SEC Form 10-Q filed by Hercules Capital Inc.

      10-Q - Hercules Capital, Inc. (0001280784) (Filer)

      5/1/25 4:16:15 PM ET
      $HTGC
      Investment Managers
      Finance

    $HCXY
    $HTGC
    $MCK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Hercules Capital upgraded by Keefe Bruyette with a new price target

      Keefe Bruyette upgraded Hercules Capital from Mkt Perform to Outperform and set a new price target of $21.50 from $19.50 previously

      12/12/24 8:09:58 AM ET
      $HTGC
      Investment Managers
      Finance
    • Mizuho resumed coverage on McKesson with a new price target

      Mizuho resumed coverage of McKesson with a rating of Neutral and set a new price target of $630.00

      12/4/24 7:43:38 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson upgraded by Robert W. Baird with a new price target

      Robert W. Baird upgraded McKesson from Neutral to Outperform and set a new price target of $688.00 from $531.00 previously

      11/7/24 6:29:13 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care

    $HCXY
    $HTGC
    $MCK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Theodosopoulos Nikos bought $28,997 worth of shares (1,608 units at $18.03), increasing direct ownership by 40% to 5,613 units (SEC Form 4)

      4 - Hercules Capital, Inc. (0001280784) (Issuer)

      8/8/24 6:50:56 PM ET
      $HTGC
      Investment Managers
      Finance
    • Director Randhawa Paramjeet K bought $52,378 worth of shares (2,898 units at $18.07), increasing direct ownership by 22% to 15,972 units (SEC Form 4)

      4 - Hercules Capital, Inc. (0001280784) (Issuer)

      8/8/24 6:50:27 PM ET
      $HTGC
      Investment Managers
      Finance
    • Director Loo Wade was granted 1,596 shares, bought $104,676 worth of shares (5,645 units at $18.54) and returned 1,596 shares to the company, increasing direct ownership by 131% to 7,150 units (SEC Form 4)

      4 - Hercules Capital, Inc. (0001280784) (Issuer)

      8/8/24 6:50:10 PM ET
      $HTGC
      Investment Managers
      Finance

    $HCXY
    $HTGC
    $MCK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • McKesson Reports Fiscal 2025 Fourth Quarter and Full Year Results and Provides Fiscal 2026 Guidance; Announces Intent to Separate Medical-Surgical Solutions

      McKesson Corporation (NYSE:MCK) has released its fiscal 2025 fourth quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Thursday, May 8th at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website, along with the company's earnings press release, financial tables, and slide presentation. Additional information about upcoming events for the investor community can be found at inves

      5/8/25 4:10:00 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • Hercules Capital Announces Date of 2025 Annual Meeting of Stockholders

      Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), will conduct its 2025 Annual Meeting of Stockholders by virtual meeting on Wednesday, June 18, 2025 at 9:00 a.m. (Eastern Time). The proxy statement for the meeting was filed on April 24, 2025 and mailed to stockholders of record as of April 17, 2025. 2025 Annual Meeting of Stockholders June 18, 2025 at 9:00 a.m. Eastern Time Virtual Meeting via Internet: http://www.virtualshareholdermeeting.com/HTGC2025 Matters to be voted on include: 1) election of three directors, 2) an advisory vote on the compensation of the Company's named executive officers, 3) authorization of the Company to sell or issue shares of its common stock

      5/8/25 6:00:00 AM ET
      $HCXY
      $HTGC
      Investment Managers
      Finance
    • Hercules Capital Reports First Quarter 2025 Financial Results

      Q1 2025 Total Gross Debt and Equity Commitments of $1.02 Billion Q1 2025 Total Gross Fundings of $539.1 Million Q1 2025 Total Investment Income of $119.5 Million Q1 2025 Net Investment Income "NII" of $77.5 Million, or $0.45 per Share Q1 2025 NII of $0.45 per Share, provides 113% Coverage of the Base Cash Distribution Received an Investment Grade Rating Upgrade to BBB (high) from Morningstar DBRS Closed Offering of $287.5 Million of 4.750% Convertible Unsecured Notes due 2028 Conservative Balance Sheet Management with Net GAAP Leverage of 97.4% and Net Regulatory Leverage of 82.7%(1) Inclusive of the Adviser Funds Advised by Hercules Adviser LLC, its Wholly-Owned Subsidiary, Hercule

      5/1/25 4:04:00 PM ET
      $HCXY
      $HTGC
      Investment Managers
      Finance

    $HCXY
    $HTGC
    $MCK
    Leadership Updates

    Live Leadership Updates

    See more
    • McKesson Signs Agreement to Acquire Controlling Interest in Florida Cancer Specialists & Research Institute's Core Ventures

      Acquisition enhances McKesson's integrated oncology platform; Florida Cancer Specialists & Research Institute to join The US Oncology Network McKesson Corporation (NYSE:MCK) announced today that it signed a definitive agreement to acquire a controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures). Core Ventures, a business and administrative services organization, was established by Florida Cancer Specialists & Research Institute, LLC (FCS), a leading physician-owned community oncology practice. FCS physicians will continue to retain a minority interest in Core Ventures. McKesson will purchase its controlling interest for approximately $2.49 bil

      8/26/24 8:00:00 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • Revelation Partners Expands Team with Hire of Andrew Olson, Partner, Chief Financial Officer & Chief Operating Officer

      SAUSALITO, Calif., Nov. 29, 2023 /PRNewswire/ -- Revelation Partners, a healthcare investment firm with over $1.5 billion of capital under management, announced today the addition of Andrew Olson as Partner, Chief Financial Officer and Chief Operating Officer. Mr. Olson has an extensive background in the venture capital and funds management industry. His addition to the team will enhance the firm's technical expertise, support the differentiated investment model, and strengthen the firm's ongoing foundation. As the firm's new Chief Financial Officer and Chief Operating Officer

      11/29/23 1:01:00 PM ET
      $HTGC
      $TPVG
      Investment Managers
      Finance
      Other Consumer Services
      Consumer Discretionary
    • KORU Medical Systems, Inc. Announces Appointment of Edward Wholihan to Its Board of Directors

      KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced that Edward Wholihan was appointed to the Company's Board of Directors on September 28, 2023 to fill the vacancy that followed the Company's 2023 Annual Meeting of Shareholders. "I am extremely proud to welcome a highly accomplished executive such as Ed to our Board of Directors. He will be a valuable addition and we will benefit from his breadth of experience and success creating shar

      10/4/23 4:05:00 PM ET
      $KRMD
      $MCK
      Medical/Dental Instruments
      Health Care
      Other Pharmaceuticals

    $HCXY
    $HTGC
    $MCK
    Financials

    Live finance-specific insights

    See more
    • McKesson Reports Fiscal 2025 Fourth Quarter and Full Year Results and Provides Fiscal 2026 Guidance; Announces Intent to Separate Medical-Surgical Solutions

      McKesson Corporation (NYSE:MCK) has released its fiscal 2025 fourth quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Thursday, May 8th at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website, along with the company's earnings press release, financial tables, and slide presentation. Additional information about upcoming events for the investor community can be found at inves

      5/8/25 4:10:00 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • Hercules Capital Announces Date of 2025 Annual Meeting of Stockholders

      Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), will conduct its 2025 Annual Meeting of Stockholders by virtual meeting on Wednesday, June 18, 2025 at 9:00 a.m. (Eastern Time). The proxy statement for the meeting was filed on April 24, 2025 and mailed to stockholders of record as of April 17, 2025. 2025 Annual Meeting of Stockholders June 18, 2025 at 9:00 a.m. Eastern Time Virtual Meeting via Internet: http://www.virtualshareholdermeeting.com/HTGC2025 Matters to be voted on include: 1) election of three directors, 2) an advisory vote on the compensation of the Company's named executive officers, 3) authorization of the Company to sell or issue shares of its common stock

      5/8/25 6:00:00 AM ET
      $HCXY
      $HTGC
      Investment Managers
      Finance
    • Hercules Capital Reports First Quarter 2025 Financial Results

      Q1 2025 Total Gross Debt and Equity Commitments of $1.02 Billion Q1 2025 Total Gross Fundings of $539.1 Million Q1 2025 Total Investment Income of $119.5 Million Q1 2025 Net Investment Income "NII" of $77.5 Million, or $0.45 per Share Q1 2025 NII of $0.45 per Share, provides 113% Coverage of the Base Cash Distribution Received an Investment Grade Rating Upgrade to BBB (high) from Morningstar DBRS Closed Offering of $287.5 Million of 4.750% Convertible Unsecured Notes due 2028 Conservative Balance Sheet Management with Net GAAP Leverage of 97.4% and Net Regulatory Leverage of 82.7%(1) Inclusive of the Adviser Funds Advised by Hercules Adviser LLC, its Wholly-Owned Subsidiary, Hercule

      5/1/25 4:04:00 PM ET
      $HCXY
      $HTGC
      Investment Managers
      Finance

    $HCXY
    $HTGC
    $MCK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by McKesson Corporation (Amendment)

      SC 13G/A - MCKESSON CORP (0000927653) (Subject)

      2/13/24 5:09:38 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed by McKesson Corporation (Amendment)

      SC 13G/A - MCKESSON CORP (0000927653) (Subject)

      1/25/24 1:48:52 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13G filed by Hercules Capital Inc.

      SC 13G - Hercules Capital, Inc. (0001280784) (Subject)

      5/8/23 5:06:26 PM ET
      $HTGC
      Investment Managers
      Finance